Skip to main
ADUS

Addus HomeCare (ADUS) Stock Forecast & Price Target

Addus HomeCare (ADUS) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 13%
Sell 13%
Strong Sell 0%

Bulls say

Addus HomeCare Corp has demonstrated impressive organic revenue growth, with rates of +12.3% year-over-year in 2023 and projected growth of +7.7% and +7.4% for 2024 and 2025 YTD, respectively. The recent +2.6% Medicare Hospice rate increase effective October 1, 2025, is expected to provide additional financial support to the company's Hospice segment, which is anticipated to maintain revenue growth of +5% to +7%. Furthermore, strategic mergers and acquisitions, alongside operational enhancements from recent leadership changes, are poised to drive further expansion and profitability for the company.

Bears say

Addus HomeCare Corp's stock faces a negative outlook due to ongoing same-store declines attributed to administrative bottlenecks in patient onboarding, resulting from Medicaid redeterminations that have led to higher discharge rates compared to admissions. The company’s dependence on Medicaid funding, which constitutes approximately 97% of its segment revenues for the year to date in 2025, creates uncertainty regarding future revenue stability amidst legislative changes such as the One Big Beautiful Bill Act. Despite demonstrating steady operational execution and a business model aligned with long-term demand trends, the disconnect between equity valuation and underlying financial performance remains a significant concern for investors.

Addus HomeCare (ADUS) has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Addus HomeCare and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Addus HomeCare (ADUS) Forecast

Analysts have given Addus HomeCare (ADUS) a Buy based on their latest research and market trends.

According to 8 analysts, Addus HomeCare (ADUS) has a Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $135.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $135.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Addus HomeCare (ADUS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.